New Zealand genetically hypertensive (GH) rats and their normotensive controls (N) rats between the ages of 10 and 16 weeks were treated with cilazapril in the diet for 6 weeks. 2. Systolic blood pressure (SBP; tail-cuff) was measured weekly and intra-arterial blood pressure (BP) was measured at the end of the treatment period. 3. The effect of cilazapril on the structure of mesenteric resistance arteries (MRA) was evaluated by both stereological and myographic techniques. 4. Cilazapril lowered SBP significantly throughout the treatment period (16 weeks; GH with cilazapril 135 +/- 5 vs GH 216 +/- 9 mmHg, P < 0.001; N cilazapril 91 +/- 6 vs N 137 +/- 3 mmHg, P < 0.001); intra-arterial BP was also significantly lowered. 5. Bodyweight (BW) of treated GH rats was significantly lower than that of untreated GH at 16 weeks (P < 0.01; t-test); however, the weight of treated N rats was not significantly affected. Ventricular mass was reduced by cilazapril in GH and N rats (GH 259 +/- 10 vs 306 +/- 11, P < 0.001; N 171 +/- 3 vs 195 +/- 4 mg/100 g BW, P < 0.001). 6. Lumen volume of MRA was not significantly affected by cilazapril in either strain; media volume was reduced by 14% in both strains and the media/lumen ratio was significantly reduced. Vascular smooth muscle cell density significantly increased in cilazapril-treated GH rats.
摘要
给10至16周龄的新西兰遗传性高血压（GH）大鼠及其血压正常的对照（N）大鼠喂食含西拉普利的饲料6周。2. 每周测量收缩压（SBP；尾套法），并在治疗期结束时测量动脉内血压（BP）。3. 通过体视学和肌动描记技术评估西拉普利对肠系膜阻力动脉（MRA）结构的影响。4. 在整个治疗期（16周），西拉普利显著降低了SBP（GH大鼠服用西拉普利后为135±5 mmHg，未服用时为216±9 mmHg，P<0.001；N大鼠服用西拉普利后为91±6 mmHg，未服用时为137±3 mmHg，P<0.001）；动脉内血压也显著降低。5. 16周时，接受治疗的GH大鼠体重（BW）显著低于未治疗的GH大鼠（P<0.01；t检验）；然而，接受治疗的N大鼠体重未受到显著影响。西拉普利使GH和N大鼠的心室质量降低（GH大鼠：259±10 vs 306±11，P<0.001；N大鼠：171±3 vs 195±4 mg/100 g BW，P<0.001）。6. 西拉普利对任一品系的MRA管腔容积均无显著影响；两个品系的中膜容积均减少了14%，中膜/管腔比值显著降低。在接受西拉普利治疗的GH大鼠中，血管平滑肌细胞密度显著增加。
